1. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002; 99: 15524-15529.
2.
Cheng J, Meng J, Zhu L, Peng Y. Exosomal noncoding RNAs in Glioma: biological functions and potential clinical applications. Mol Cancer 2020; 19: 66.
3.
Cheng M, Zhang ZW, Ji XH, Xu Y, Bian E, Zhao B. Super-enhancers: A new frontier for glioma treatment. Biochim Biophys Acta Rev Cancer 2020; 1873: 188353.
4.
Correia de Sousa M, Gjorgjieva M, Dolicka D, Sobolewski C, Foti M. Deciphering miRNAs’ action through miRNA editing. Int J Mol Sci 2019; 20: 6249.
5.
Di W, Fan W, Wu F, Shi Z, Wang Z, Yu M, Zhai Y, Chang Y, Pan C, Li G, Kahlert UD, Zhang W. Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples. Cancer Sci 2022; 113: 756-769.
6.
Diao Y, Jin B, Huang L, Zhou W. MiR-129-5p inhibits glioma cell progression in vitro and in vivo by targeting TGIF2. J Cell Mol Med 2018; 22: 2357-2367.
7.
Ferragut Cardoso AP, Udoh KT, States JC. Arsenic-induced changes in miRNA expression in cancer and other diseases. Toxicol Appl Pharmacol 2020; 409: 115306.
8.
Fox JL, Dews M, Minn AJ, Thomas-Tikhonenko A. Targeting of TGFbeta signature and its essential component CTGF by miR-18
9.
correlates with improved survival in glioblastoma. RNA 2013; 19: 177-190.
10.
Hao J, Wei H, Qi Y, Liu H. miR-129-5p plays an anticancer role in colon cancer by targeting RSF1. Cell Mol Biol (Noisy-le-grand) 2022; 67: 196-201.
11.
He B, Zhao Z, Cai Q, Zhang Y, Zhang P, Shi S, Xie H, Peng X, Yin W, Tao Y, Wang X. miRNA-based biomarkers, therapies, and resistance in cancer. Int J Biol Sci 2020; 16: 2628-2647.
12.
Hussen BM, Hidayat HJ, Salihi A, Sabir DK, Taheri M, Ghafouri-Fard S. MicroRNA: A signature for cancer progression. Biomed Pharmacother 2021; 138: 111528.
13.
Ji B, Chen L, Cai Q, Guo Q, Chen Z, He D. Identification of an 8-miRNA signature as a potential prognostic biomarker for glioma. PeerJ 2020; 8: e9943.
14.
Jiang H, Gong R, Wu Y. miR-129-5p inhibits oxidized low-density lipoprotein-induced A7r5 cell viability and migration by targeting HMGB1 and the PI3k/Akt signaling pathway. Exp Ther Med 2022; 23: 243.
15.
Li S, Xie X, Peng F, Du J, Peng C. Regulation of temozolomide resistance via lncRNAs: Clinical and biological properties of lncRNAs in gliomas (Review). Int J Oncol 2022; 61: 101.
16.
Liu C, Ge YY, Xie XX, Luo B, Shen N, Liao XS, Bi SQ, Xu T, Xiao SW, Zhang QM. Identification of dysregulated microRNAs in glioma using RNA-sequencing. Curr Med Sci 2021; 41: 356-367.
17.
Liu J, Cheng C, Jiao J, Huang W, Huang J, Sun J, Shao J. Mirco-RNA-129-5p suppresses the development of glioma by targeting HOXC10. Pathol Res Pract 2020; 216: 152868.
18.
Liu Y, Liang G, Wang H, Liu Z. MicroRNA-129-5p suppresses proliferation, migration and invasion of retinoblastoma cells through PI3K/AKT signaling pathway by targeting PAX6. Pathol Res Pract 2019; 215: 152641.
19.
Lu GF, Geng F, Xiao Z, Chen YS, Han Y, You CY, Gong NL, Xie ZM, Pan M. MicroRNA-6807-3p promotes the tumorigenesis of glioma by targeting downstream DACH1. Brain Res 2019; 1708: 47-57.
20.
Miricescu D, Totan A, Stanescu-Spinu II, Badoiu SC, Stefani C, Greabu M. PI3K/AKT/mTOR signaling pathway in breast cancer: From molecular landscape to clinical aspects. Int J Mol Sci 2020; 22: 173.
21.
Montalto FI, De Amicis F. Cyclin D1 in cancer: A molecular connection for cell cycle control, adhesion and invasion in tumor and stroma. Cells 2020; 9: 2648.
22.
Noorolyai S, Shajari N, Baghbani E, Sadreddini S, Baradaran B. The relation between PI3K/AKT signalling pathway and cancer. Gene 2019; 698: 120-128.
23.
Ochocka N, Segit P, Walentynowicz KA, Wojnicki K, Cyranow-ski S, Swatler J, Mieczkowski J, Kaminska B. Single-cell RNA sequencing reveals functional heterogeneity of glioma-associated brain macrophages. Nat Commun 2021; 12: 1151.
24.
Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015. Neuro Oncol 2018; 20 (suppl 4): iv1-iv86.
25.
Peng D, Luo L, Zhang X, Wei C, Zhang Z, Han L. CircRNA: An emerging star in the progression of glioma. Biomed Pharmacother 2022; 151: 113150.
26.
Sallam M, Mysara M, Baatout S, Guns PJ, Ramadan R, Benotmane MA. Meta-analysis of RNA-seq datasets identifies novel players in glioblastoma. Cancers (Basel) 2022; 14: 5788.
27.
Shi C, Luo W, Sun C, Yu L, Zhou X, Hua D, Jiang Z, Wang Q, Yu S. The miR-29 family members induce glioblastoma cell apoptosis by targeting cell division cycle 42 in a p53-dependent manner. Eur J Clin Invest 2023; 53: e13964.
28.
Svensson A, Özen I, Genové G, Paul G, Bengzon J. Endogenous brain pericytes are widely activated and contribute to mouse glioma microvasculature. PLoS One 2015; 10: e0123553.
29.
Tchakarska G, Sola B. The double dealing of cyclin D1. Cell Cycle 2020; 19: 163-178.
30.
Wan S, Moure UAE, Liu R, Liu C, Wang K, Deng L, Liang P, Cui H. Combined bulk RNA-seq and single-cell RNA-seq identifies a necroptosis-related prognostic signature associated with inhibitory immune microenvironment in glioma. Front Immunol 2022; 13: 1013094.
31.
Wang H, Li H, Yu Y, Jiang Q, Zhang R, Sun H, Xing W, Li Y. Long non-coding RNA XIST promotes the progression of esophageal squamous cell carcinoma through sponging miR-129-5p and upregulating CCND1 expression. Cell Cycle 2021; 20: 39-53.
32.
Wang L, Liu Y, Yu Z, Gong J, Deng Z, Ren N, Zhong Z, Cai H, Tang Z, Cheng H, Chen S, He Z. Mir-139-5p inhibits glioma cell proliferation and progression by targeting GABRA1. J Transl Med 2021; 19: 213.
33.
Wang Q, Wu S, Gu Y, Liang H, He F, Wang X, He D, Wu K. RASAL2 regulates the cell cycle and cyclin D1 expression through PI3K/AKT signalling in prostate tumorigenesis. Cell Death Discov 2022; 8: 275.
34.
Wei C, Wang B, Peng D, Zhang X, Li Z, Luo L, He Y, Liang H, Du X, Li S, Zhang S, Zhang Z, Han L, Zhang J. Pan-cancer analysis shows that ALKBH5 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including gliomas. Front Immunol 2022; 13: 849592.
35.
Xiao B, Lv SG, Wu MJ, Liang Y, Liu R, Wang N, Yang G. Circ_CLIP2 promotes glioma progression through targeting the miR-195-5p/HMGB3 axis. J Neurooncol 2021; 154: 131-144.
36.
Xu C, Du Z, Ren S, Liang X, Li H. MiR-129-5p sensitization of lung cancer cells to etoposide-induced apoptosis by reducing YWHAB. J Cancer 2020; 11: 858-866.
37.
Xu X, Liang Y, Gareev I, Liang Y, Liu R, Wang N, Yang G. LncRNA as potential biomarker and therapeutic target in glioma. Mol Biol Rep 2023; 50: 841-851.
38.
Yin X, Gao J, Liu Z, Han M, Ji X, Wang Z, Li Y, He D, Zhang F, Liu Q, Xin T. Mechanisms of long non-coding RNAs in biological phenotypes and ferroptosis of glioma. Front Oncol 2022; 12: 941327.
39.
Yoshida K, Yokoi A, Yamamoto Y, Kajiyama H. ChrXq27.3 miRNA cluster functions in cancer development. J Exp Clin Cancer Res 2021; 40: 112.
40.
Yu J, Zhang X, Ma Y, Li Z, Tao R, Chen W, Xiong S, Han X. MiR-129-5p restrains apatinib resistance in human gastric cancer cells via downregulating HOXC10. Cancer Biother Radiopharm 2021; 36: 95-105.
41.
Yu Y, Zuo W, Cai W, Xu Y, Liu W, Zhao Z. MiR-129-5p suppresses cell proliferation of human osteosarcoma cancer by down-regulating lncRNA lnc712. Cancer Manag Res 2021; 13: 2259-2264.
42.
Yu Z, Liu Y, Li Y, Zhang J, Peng J, Gong J, Xia Y, Wang L. miRNA-338-3p inhibits glioma cell proliferation and progression by targeting MYT1L. Brain Res Bull 2022; 179: 1-12.
